AstraZeneca’s Saphnelo SC Poised to Challenge GSK’s Benlysta in SLE Market

Event summary

  • AstraZeneca’s Saphnelo SC is emerging as a key challenger to GSK’s Benlysta in the systemic lupus erythematosus (SLE) market.
  • A chart audit of 1,040 moderate-to-severe SLE patients conducted between January 29 and March 5, 2026, shows biologic use reaching nearly 60% of patients.
  • Saphnelo’s use is increasingly associated with dermatologic-driven disease, with over one-quarter of Saphnelo-treated patients previously receiving Benlysta.
  • The anticipated U.S. launch of subcutaneous Saphnelo is expected to reduce administration barriers and expand access, signaling share erosion risk for Benlysta.

The big picture

The SLE market is evolving toward biologic-driven care, with increasing treatment complexity and intensifying competition. The anticipated launch of Saphnelo SC by AstraZeneca is set to challenge GSK’s Benlysta, while a robust pipeline of targeted therapies aims to further reshape the landscape. This shift underscores the growing emphasis on achieving deeper and more durable disease control in SLE treatment.

What we're watching

Competitive Dynamics
How AstraZeneca’s Saphnelo SC will affect GSK’s Benlysta market share following its U.S. launch.
Therapeutic Innovation
Whether the growing adoption of biologic therapies will further reduce reliance on conventional immunosuppressants.
Pipeline Advancements
The pace at which emerging therapies like litifilimab and next-generation B-cell-directed treatments will enter the market.